Literature DB >> 19691

Syrup of ipecacuanha as an emetic in adults.

K F Ilett, S M Gibb, R W Unsworth.   

Abstract

The emetic actions of syrup of ipecacuanha have been evaluated in 105 adult patients presenting at the emergency department of the Royal Perth Hospital with a diagnosis of accidental or intentional poisoning. The australian Pharmaceutical Formulary (APF) and the United States Pharmacopeia (USP) formulations of the syrup were compared and gave similar overall emetic responses of 88% and 89% respectively at a dose level of 15 ml. A 30 ml dose regimen of the APF formulation gave a slightly but not significantly increased overall emetic response of 96%. There were no differences between the three groups of patients in the time taken to vomit, the duration of vomiting or the volume of stomach contents recovered.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 19691

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

Review 1.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Syrup of ipecacuanha: is it really useful?

Authors:  J A Vale; T J Meredith; A T Proudfoot
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-22

Review 3.  Clinical toxicology.

Authors:  J A Vale
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

4.  Emergency treatment for swallowed poisons.

Authors:  R W Unsworth; S M Gibb; K F Ilett
Journal:  J R Soc Med       Date:  1978-07       Impact factor: 18.000

5.  Ipecacuahana induced emesis in the treatment of self-poisoned adults.

Authors:  G Gordon
Journal:  Arch Emerg Med       Date:  1985-12

6.  First aid interventions by laypeople for acute oral poisoning.

Authors:  Bert Avau; Vere Borra; Anne-Catherine Vanhove; Philippe Vandekerckhove; Peter De Paepe; Emmy De Buck
Journal:  Cochrane Database Syst Rev       Date:  2018-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.